TAUG Continues to Increase its National Network of DSD Distributors to Support Ongoing National Launch of its Flagship Brand
September 29 2020 - 11:18AM
InvestorsHub NewsWire
NEW YORK, NY -- September 29, 2020 -- InvestorsHub
NewsWire -- Tauriga Sciences, Inc. (OTCQB: TAUG)
(“Tauriga” or the “Company”), a revenue generating, diversified
life sciences company, with a proprietary line of functional
“supplement” chewing gums (Flavors: Pomegranate, Blood Orange,
Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two
ongoing Biotechnology initiatives, today announced the assembling
of a national network of Direct Store Delivery (“DSD”) Distributors
in support of the ongoing national launch of its flagship brand
Tauri-Gum™. Through its previously disclosed Agreement
with Mr. Checkout Distributors (“Mr. Checkout”), the Company is
continually increasing its network of DSD Distributors – which have
the capability to place Tauri-Gum™ in many thousands of retail
locations across the country. The Company plans to issue
future updates, as this national network continues to grow and
strengthen.
In other news, the Company has entered into a major
Joint Venture Partnership (“JVP” or “Partnership”) with a Los
Angeles based firm. Full details of this important
alliance and its positive attributes will be disclosed over the
coming days.
ABOUT TAURIGA SCIENCES
INC.
Tauriga Sciences, Inc. (TAUG)
is a revenue generating, diversified life sciences company, engaged
in several major business activities and
initiatives. The company manufactures and distributes
several proprietary retail products and product lines, mainly
focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles
market segment. The main product line, branded as
Tauri-Gum™, consists of a proprietary supplement chewing gum that
is both Kosher certified and Vegan formulated (CBD Infused
Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate) & (CBG
Infused Tauri-Gum™ Flavor: Peach-Lemon). The Company’s
commercialization strategy consists of a broad array of retail
customers, distributors, and a fast-growing E-Commerce business
segment (E-Commerce website: www.taurigum.com). Please visit our
corporate website, for additional information, as well as
inquiries, at http://www.tauriga.com
Complementary to the Company’s retail business, are
its two ongoing biotechnology initiatives. The first one
relates to the development of a Pharmaceutical grade version of
Tauri-Gum™, for nausea regulation (specifically designed to help
patients that are subjected to ongoing chemotherapy
treatment). On March 18, 2020, the Company announced
that it filed a provisional U.S. patent application covering its
pharmaceutical grade version of Tauri-Gum™. The Patent,
filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS,
METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. The
second one relates to a collaboration agreement with Aegea
Biotechnologies Inc. for the co-development of a rapid,
multiplexed, Novel Coronavirus (COVID-19) test with superior
sensitivity and
selectivity.
The Company is headquartered in New York City and
operates a regional office in Barcelona, Spain. In
addition, the Company operates a full time E-Commerce fulfillment
center located in LaGrangeville, New
York.
DISCLAIMER -- Forward-Looking
Statements
This press release contains certain
“forward-looking statements” as defined by the Private Securities
Litigation Reform Act of 1995 which represent management’s beliefs
and assumptions concerning future events. These forward-looking
statements are often indicated by using words such as “may,”
“will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or
plans, and may include statements regarding corporate objectives as
well as the attainment of certain corporate goals and milestones.
Forward-looking statements are based on present circumstances and
on management’s present beliefs with respect to events that have
not occurred, that may not occur, or that may occur with different
consequences or timing than those now assumed or anticipated.
Actual results may differ materially from those expressed
in forward looking statements due to known and unknown
risks and uncertainties, such as are not guarantees of general
economic and business conditions, the ability to successfully
develop and market products, consumer and business consumption
habits, the ability to consummate successful acquisition and
licensing transactions, fluctuations in exchange rates, and other
factors over which Tauriga has little or no control. Many of these
risks and uncertainties are discussed in greater detail in the
“Risk Factors” section of Tauriga’s Form 10-K and other filings
made from time to time with the Securities and Exchange Commission.
Such forward-looking statements are made only as of the date of
this release, and Tauriga assumes no obligation to update
forward-looking statements to reflect subsequent events or
circumstances. You should not place undue reliance on these
forward-looking
statements.
CONTACT:
Tauriga Sciences,
Inc.
555 Madison Avenue, 5th
Floor
New York,
NY 10022
Chief Executive
Officer
Mr. Seth M.
Shaw
Email: sshaw@tauriga.com
cell # (917) 796
9926
Instagram:
@taurigum
Twitter:
@SethMShaw
Corp. Website: www.tauriga.com
E-Commerce Website: www.taurigum.com
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Apr 2023 to Apr 2024